NOT-AI-18-034: Notice of Change to the NIAID Specific Areas of Research Interest for PA-18-723 "Improving Patient Adherence to Treatment and Prevention Regimens to Promote Health (R21 Clinical Trial Optional)"

Notice of Change to the NIAID Specific Areas of Research Interest for PA-18-723 "Improving Patient Adherence to Treatment and Prevention Regimens to Promote Health (R21 Clinical Trial Optional)"

Notice Number: NOT-AI-18-034

Key Dates
Release Date: April 27, 2018

Related Announcements
PA-18-723

Issued by
Office of Behavioral and Social Sciences Research (OBSSR)
National Cancer Institute (NCI)
National Institute on Aging (NIA)
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
National Institute of Allergy and Infectious Diseases (NIAID)
National Institute on Drug Abuse (NIDA)
National Institute of Mental Health (NIMH)
National Institute of Nursing Research (NINR)
National Institute on Minority Health and Health Disparities (NIMHD)

Purpose

The purpose of this Notice is to update the NIAID specific area of research interest for PA-18-723 "Improving Patient Adherence to Treatment and Prevention Regimens to Promote Health (R21 Clinical Trial Optional)".

Part 2. Section I. Funding Opportunity Description

Research Objectives

Current language:

The National Institute of Allergies and Infectious Disease (NIAID) is interested in supporting programs that support the development of biomedical measures to improve adherence to ART, PrEP, and other HIV prevention interventions and strategies. NIAID is also interested in supporting basic and applied research in the behavioral and social sciences to inform the development of novel interventions that enable all HIV infected individuals to achieve durable viral suppression. With implementers, develop and pilot enhanced adherence interventions with demonstrated effectiveness.

Revised language:

The National Institute of Allergy and Infectious Diseases (NIAID) is interested in basic and applied research to inform the development of novel interventions to improve adherence to treatment and prevention of infectious disease. NIAID is also interested in the integration of biomedical and behavioral research strategies to encourage more personalized approaches to therapy, increased patient adherence to drug dosing instructions and compliance with screening and retesting recommendations.

NIAID will not fund multi-site efficacy or effectiveness research through this FOA (please see other NIAID Funding Opportunities instead); single-site efficacy or effectiveness research studies are allowed. Investigators are strongly encouraged to discuss their plans with NIAID program staff prior to submitting their application.

All other aspects of this FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Usha Sharma, Ph.D.
National Institute of Allergy and Infectious Diseases (NIAID)
Telephone: 240-292-4809
Email: [email protected]